Christine H.N.C. Thai

Christine H.N.C. Thai

Auto-generated profile, based on publicly available information

Christine H.N.C. Thai

University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
AWAustin A. Whitman
Austin A. Whitman
RKRasha Kakati
Rasha Kakati
SHSantiago Haase
Santiago Haase
CTChristine H.N.C. Thai
Christine H.N.C. Thai
STSurya Kant Tripathi
Surya Kant Tripathi
PSPhilip M Spanheimer
Philip M Spanheimer
Resistance to endocrine therapy (ET) is common in estrogen receptor–positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient-derived organoids (PDO). Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen-responsive luminal A–like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor bead–mass spectrometry revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Cotreatment with the HER2 inhibitor lapatinib further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ PDO and patient-derived xenograft models. Future studies should evaluate whether signatures predict responses in patients with ER+ breast tumors and determine the role of cotargeting HER2 signaling with vandetanib therapy.